Table 1.
Baseline characteristics before and after multi-group inverse probability treatment weighting
| Before weighting | After weighting | |||||||
| BNT162b2 | CoronaVac | None | SMD | BNT162b2 | CoronaVac | None | SMD | |
| N | 653 | 671 | 4169 | 3893.56 | 4051.97 | 4169 | ||
| Male (N (%)) | 136 (20.8) | 194 (28.9) | 850 (20.4) | 0.132 | 681.6 (17.5) | 865.8 (21.4) | 850.0 (20.4) | 0.065 |
| Age (mean (SD)) | 55.83 (11.89) | 59.52 (11.04) | 63.97 (14.73) | 0.424 | 61.98 (12.38) | 61.60 (10.85) | 63.97 (14.73) | 0.12 |
| Comorbidities (N (%)) | ||||||||
| Asthma | 9 (1.4) | 9 (1.3) | 72 (1.7) | 0.021 | 53.6 (1.4) | 55.7 (1.4) | 72.0 (1.7) | 0.019 |
| Cerebrovascular disease | 6 (0.9) | 18 (2.7) | 230 (5.5) | 0.18 | 163.9 (4.2) | 166.0 (4.1) | 230.0 (5.5) | 0.044 |
| Chronic obstructive pulmonary disease | 12 (1.8) | 16 (2.4) | 235 (5.6) | 0.135 | 218.7 (5.6) | 264.4 (6.5) | 235.0 (5.6) | 0.025 |
| Congestive heart failure | 1 (0.2) | 2 (0.3) | 118 (2.8) | 0.153 | 120.5 (3.1) | 50.7 (1.3) | 118.0 (2.8) | 0.085 |
| Chronic renal failure | 0 (0.0) | 5 (0.7) | 76 (1.8) | 0.137 | 0.0 (0.0) | 72.9 (1.8) | 76.0 (1.8) | 0.129 |
| Dementia | 0 (0.0) | 0 (0.0) | 17 (0.4) | 0.06 | 0.0 (0.0) | 0.0 (0.0) | 17.0 (0.4) | 0.06 |
| Diabetes | 29 (4.4) | 45 (6.7) | 488 (11.7) | 0.18 | 503.8 (12.9) | 384.3 (9.5) | 488.0 (11.7) | 0.073 |
| Mild liver disease | 0 (0.0) | 1 (0.1) | 13 (0.3) | 0.056 | 0.0 (0.0) | 3.8 (0.1) | 13.0 (0.3) | 0.057 |
| Moderate-severe liver disease | 1 (0.2) | 0 (0.0) | 1 (0.0) | 0.04 | 0.0 (0.0) | 0.0 (0.0) | 1.0 (0.0) | 0.015 |
| Myocardial infarction | 4 (0.6) | 1 (0.1) | 48 (1.2) | 0.086 | 25.8 (0.7) | 82.8 (2.0) | 48.0 (1.2) | 0.081 |
| Peripheral vascular disease | 0 (0.0) | 1 (0.1) | 39 (0.9) | 0.1 | 0.0 (0.0) | 27.7 (0.7) | 39.0 (0.9) | 0.094 |
| Paralysis | 0 (0.0) | 1 (0.1) | 17 (0.4) | 0.065 | 0.0 (0.0) | 7.6 (0.2) | 17.0 (0.4) | 0.064 |
| Respiratory infections | 20 (3.1) | 23 (3.4) | 390 (9.4) | 0.176 | 278.5 (7.2) | 354.8 (8.8) | 390.0 (9.4) | 0.053 |
| Stroke or systemic embolism | 2 (0.3) | 7 (1.0) | 95 (2.3) | 0.121 | 73.5 (1.9) | 56.4 (1.4) | 95.0 (2.3) | 0.044 |
| Ulcers | 3 (0.5) | 14 (2.1) | 106 (2.5) | 0.116 | 80.1 (2.1) | 97.7 (2.4) | 106.0 (2.5) | 0.022 |
| Viral infections | 0 (0.0) | 2 (0.3) | 43 (1.0) | 0.104 | 0.0 (0.0) | 36.9 (0.9) | 43.0 (1.0) | 0.097 |
| Health service utilisation (N (%)) | ||||||||
| Emergency or hospital admission | 471 (72.1) | 508 (75.7) | 3464 (83.1) | 0.177 | 3185.5 (81.8) | 3327.5 (82.1) | 3464.0 (83.1) | 0.022 |
| Outpatient visits | 641 (98.2) | 665 (99.1) | 4122 (98.9) | 0.054 | 3826.2 (98.3) | 4011.8 (99.0) | 4122.0 (98.9) | 0.043 |
| Medication usage within 90 days (N (%)) | ||||||||
| Immunosuppressants | 11 (1.7) | 7 (1.0) | 134 (3.2) | 0.102 | 82.0 (2.1) | 115.4 (2.8) | 134.0 (3.2) | 0.046 |
| NSAIDs | 284 (43.5) | 295 (44.0) | 1617 (38.8) | 0.07 | 1529.5 (39.3) | 1671.0 (41.2) | 1617.0 (38.8) | 0.033 |
| Corticosteroids | 0 (0.0) | 0 (0.0) | 1 (0.0) | 0.015 | 0.0 (0.0) | 0.0 (0.0) | 1.0 (0.0) | 0.015 |
| b/tsDMARDs | 191 (29.2) | 187 (27.9) | 1287 (30.9) | 0.044 | 1230.7 (31.6) | 1418.6 (35.0) | 1287.0 (30.9) | 0.059 |
| csDMARDs | 486 (74.4) | 508 (75.7) | 3041 (72.9) | 0.042 | 2767.6 (71.1) | 2988.2 (73.7) | 3041.0 (72.9) | 0.04 |
| Drugs for gout | 9 (1.4) | 26 (3.9) | 120 (2.9) | 0.105 | 79.7 (2.0) | 93.1 (2.3) | 120.0 (2.9) | 0.036 |
bDMARDs, biological disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; NSAIDs, Non-steroidal anti-inflammatory drugs; SMD, standardised mean difference; tsDMARDs, target synthetic disease-modifying antirheumatic drugs.